Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01061671 · ClinicalTrials.gov registry record · Phase 3
Simvastatin Therapy for Moderate and Severe COPD
A Phase 3 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 3
- Development phase
- 885
- Enrollment target
NCT01061671: Clinical Trial Phase 3 study, sponsored by University of Minnesota.
NCT01061671 is a Phase 3 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 885 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01061671, a Phase 3 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 885 participants
- Enrollment target
Study Summary
To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do not have other indications for statin treatment.
Interventions
- DRUG Placebo
- DRUG simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 885 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Why NCT01061671 stopped before completion
NCT01061671 is an interventional study that assigns participants to a tested intervention. The registered 885 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01061671 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01061671 about?
NCT01061671 is a clinical study titled "Simvastatin Therapy for Moderate and Severe COPD". To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do not have other indicati...
What is the current status of trial NCT01061671?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 885 participants. The study started on 2010-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01061671?
The interventions under investigation include: Placebo (DRUG), simvastatin (DRUG).
Who is sponsoring clinical trial NCT01061671?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01061671's enrollment target sits among peer trials
885 365th of 2000 higher than 1,635 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia